Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

RSV-NET data showed that RSV hospitalization rates among infants aged 0 to 7 months were an estimated 43% (95% confidence ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein vaccine (Abrysvo) or nirsevimab (Beyfortus), Stephanie Irving, MHS, of the ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

By Dr. Priyom Bose, Ph.D.Real-world data from Madrid hospitals show dramatic declines in infant ICU stays, hospital days, and RSV-related admissions after nirsevimab immunization campaign. ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence.

A total of 69 infants (median age at admission, 2.7 months; 56.5% boys) who received nirsevimab and were hospitalised for RSV-related LRTI were included. Cases were classified as breakthrough (n ...

HealthDay News — In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized against respiratory syncytial virus (RSV).

Nirsevimab is a seasonal immunization that targets RSV in infants. As a monoclonal antibody—a protein that can bind to a specific target—nirsevimab binds to a particular area of the virus and ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...